Clinical trial
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer…
NCT00326898 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00326898 |
|---|---|
| Title | Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery |
| Official title | ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma |
| Acronym | ASSURE |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | Cancer and Leukemia Group B NCIC Clinical Trials Group SWOG Cancer Research Network |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7 |
| Intervention type | Drug, Other |
| Interventions | Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment, Sorafenib Tosylate, Sunitinib Malate |
| Enrollment | 1,943 |
| Start date | Apr 24, 2006 |
| Primary completion | Aug 27, 2015 |
| Completion | Sep 1, 2021 |
| First posted | May 17, 2006 |
| Last update posted | Feb 8, 2022 |
| Countries | Canada, Puerto Rico, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: